Guided Anti-P2Y12 Therapy in Patients Undergoing Percutaneous Coronary Intervention
M Cattaneo, A Squizzato, S Birocchi… - Thrombosis and …, 2024 - thieme-connect.com
Dear Editor, We read with interest the comprehensive editorial by Landolina and
collaborators, 1 commenting our systematic reviews with meta-analyses of randomized …
collaborators, 1 commenting our systematic reviews with meta-analyses of randomized …
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study
Aims Based on recent clinical data, the 2020 ESC guidelines on non-ST-elevation acute
coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual …
coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual …
Smoking and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: A substudy from the randomized PATH‐PCI trial
Y Pan, TT Wu, CJ Deng, Y Yang, XG Hou… - Clinical …, 2024 - Wiley Online Library
Background This is a sub‐analysis of the Personalized Antithrombotic Therapy for Coronary
Heart Disease after PCI (PATH‐PCI) trial in China to explore the relationship between …
Heart Disease after PCI (PATH‐PCI) trial in China to explore the relationship between …
The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary …
MA Akkaif, NAA Daud, DAM Noor, A Sha'aban… - … Drugs and Therapy, 2024 - Springer
Abstract Background In the Asian population, the presence of the CYP2C19 loss-of-function
(LOF) allele is a known genetic variation. This allele is associated with a reduced capacity to …
(LOF) allele is a known genetic variation. This allele is associated with a reduced capacity to …
Antiplatelet therapy guided by CYP2C19 point-of-care pharmacogenetics plus multidimensional treatment decisions
V Voicu, N Diehm, I Moarof, S Parejo… - …, 2024 - Future Medicine
Aim: Implementation of CYP2C19 point-of-care (POC) pharmacogenetic (PGx) testing with
personalized treatment recommendations. Methods: POC CYP2C19 genotyping plus expert …
personalized treatment recommendations. Methods: POC CYP2C19 genotyping plus expert …
Antiplatelet therapy and bleeding outcomes with CYP2C19 genotyping
JC Coons, JM Stevenson, A Patel… - Journal of …, 2022 - journals.sagepub.com
Purpose: The impact of antiplatelet therapy with availability of CYP2C19 genotyping on
bleeding in a real-world setting has not been extensively studied. Methods: Prospective …
bleeding in a real-world setting has not been extensively studied. Methods: Prospective …
Ticagrelor Versus Clopidogrel in Minor Stroke or Transient Ischemic Attack With Intracranial Artery Stenosis: A Post Hoc Analysis of CHANCE‐2
C Wang, W Jia, J Jing, X Meng, A Wang… - Journal of the …, 2023 - Am Heart Assoc
Background This study aimed to investigate the efficacy and safety of ticagrelor–aspirin
versus clopidogrel–aspirin in Chinese patients by the presence and clinical presentation of …
versus clopidogrel–aspirin in Chinese patients by the presence and clinical presentation of …
Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment
M Galli, G Gargiulo - Journal of Thrombosis and Thrombolysis, 2022 - Springer
Antithrombotic therapy is the cornerstone for the treatment and prevention of ischemic
events among both acute (ACS) or chronic coronary syndromes (CCS)[1, 2]. Nevertheless …
events among both acute (ACS) or chronic coronary syndromes (CCS)[1, 2]. Nevertheless …
Tongue diagnostic parameters-based diagnostic signature in coronary artery disease patients with clopidogrel resistance after percutaneous coronary intervention
B Liang, R Li, J Lu, XJ Tian, N Gu - EXPLORE, 2023 - Elsevier
Background Credible diagnostic stratification remains a challenge for coronary artery
disease patients with clopidogrel resistance after percutaneous coronary intervention …
disease patients with clopidogrel resistance after percutaneous coronary intervention …
[HTML][HTML] Which future for aspirin in acute coronary syndromes treated with percutaneous coronary intervention? An overview on aspirin-free strategies
Low-dose aspirin currently represents the milestone of antiplatelet therapy for patients with
coronary artery disease (CAD), with proven efficacy in reducing recurrent ischemic events [1 …
coronary artery disease (CAD), with proven efficacy in reducing recurrent ischemic events [1 …